Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium.


Journal

Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498

Informations de publication

Date de publication:
15 08 2023
Historique:
received: 06 04 2023
revised: 26 05 2023
accepted: 19 06 2023
medline: 2 8 2023
pubmed: 26 6 2023
entrez: 25 6 2023
Statut: ppublish

Résumé

Several studies indicated leukocyte telomere length (LTL) as a biomarker of multiple sclerosis (MS) evolution. This study aimed to investigate LTL in women with multiple sclerosis (MS) compared to that in healthy women (HW) across different reproductive phases, and to evaluate its relationship with MS activity. Blood samples were collected from women with MS and HW during the fertile phase, pregnancy, and puerperium. LTL was determined using quantitative fluorescence in situ hybridization (Q-FISH). Blood samples from 68 women with MS (22 during fertile life, 23 during pregnancy, and 23 post-partum) and 52 HW (23 during fertile life, 20 during pregnancy, and 9 post-partum) were analyzed. During pregnancy, LTL in MS women and HW was 84.7 ± 10.5 and 77.6 ± 11.5, respectively (p < 0.005). Regression analysis showed that shorter LTL was associated with pregnancy in HW (p = 0.021); this relationship was not observed in MS women, for whom shorter LTL was related to a higher EDSS (p = 0.036). A longitudinal analysis was performed in eight MS women, showing LTL shortening from pregnancy to puerperium (p = 0.003), which was related to MS reactivation (p = 0.042). Our results highlight the possible associations between LTL, reproductive biological phases, and MS activity after delivery.

Identifiants

pubmed: 37356355
pii: S0165-5728(23)00123-6
doi: 10.1016/j.jneuroim.2023.578137
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

578137

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Lorefice L., Fenu G., Frau J, and Cocco E. received honoraria for consultancy or speaking from Biogen, Novartis, Sanofi, Genzyme, Serono and Teva and Almirall. Caria P., Pilotto S., D'Alterio MN, Fronza M., Murgia F., Dettori T., Frau DV, Atzori L., and Angioni S., have nothing to disclose.

Auteurs

P Caria (P)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

S Pilotto (S)

Multiple Sclerosis Center, Binaghi Hospital, ASL Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Italy.

M N D'Alterio (MN)

Division of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.

M Fronza (M)

Multiple Sclerosis Center, Binaghi Hospital, ASL Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Italy.

F Murgia (F)

Clinical Metabolomics Unit, Department of Biomedical Sciences, University of Cagliari, Italy.

J Frau (J)

Multiple Sclerosis Center, Binaghi Hospital, ASL Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Italy.

G Fenu (G)

Department of Neurosciences, ARNAS Brotzu, Cagliari, Italy.

T Dettori (T)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

D V Frau (DV)

Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.

L Atzori (L)

Clinical Metabolomics Unit, Department of Biomedical Sciences, University of Cagliari, Italy.

S Angioni (S)

Division of Gynecology and Obstetrics, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.

E Cocco (E)

Multiple Sclerosis Center, Binaghi Hospital, ASL Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Italy.

L Lorefice (L)

Multiple Sclerosis Center, Binaghi Hospital, ASL Cagliari, Department of Medical Sciences and Public Health, University of Cagliari, Italy. Electronic address: lorena.lorefice@hotmail.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH